Zonisamide Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IB/0013 
C.I.2.a - Change in the SPC, Labelling or PL of a 
07/06/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
IB/0011/G 
This was an application for a group of variations. 
20/07/2022 
n/a 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IAIN/0012 
A.5.a - Administrative change - Change in the name 
14/07/2022 
and/or address of a manufacturer/importer 
responsible for batch release 
Annex II and 
PL 
T/0010 
Transfer of Marketing Authorisation 
24/09/2021 
15/11/2021 
SmPC, 
Labelling and 
PL 
IB/0009 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
15/04/2021 
15/11/2021 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
R/0008 
Renewal of the marketing authorisation. 
17/09/2020 
01/12/2020 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II and PL 
the CHMP considered that the benefit-risk balance of 
Zonisamide Mylan in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IA/0007/G 
This was an application for a group of variations. 
22/05/2020 
n/a 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
N/0006 
Minor change in labelling or package leaflet not 
20/11/2019 
01/12/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 3/4 
 
 
 
 
 
 
 
 
N/0005 
Minor change in labelling or package leaflet not 
05/03/2019 
01/12/2020 
PL 
connected with the SPC (Art. 61.3 Notification) 
IB/0004 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
26/03/2018 
02/04/2019 
SmPC and PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IB/0003 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
07/09/2017 
02/04/2019 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IA/0002 
B.I.a.3.a - Change in batch size (including batch size 
20/07/2017 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
IB/0001/G 
This was an application for a group of variations. 
17/03/2017 
02/04/2019 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
